Hallux develops a new topical dosage form and route of administration for treating onychomycosis.
Hallux has raised $9.4M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in April 2022.
Hallux's investors include Deerfield.
Hallux is headquartered in Laguna Hills, United States.
Hallux develops a new topical dosage form and route of administration for treating onychomycosis.
Hallux is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Hallux — Funding & Investors." VCBacked, April 13, 2022, https://www.vcbacked.co/company/hallux. Accessed September 30, 2026.
VCBacked. (2022). Hallux — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/hallux
{{cite web |title=Hallux — Funding & Investors |url=https://www.vcbacked.co/company/hallux |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated